BioNTech and Moderna were both developing & conducting mRNA vaccine clinical trials just months before Dec 2019 Wuhan outbreak

“As personalized mRNA vaccines go through trials, Moderna, BioNTech and CureVac, based in Tübingen, Germany, are simultaneously developing off-the-shelf vaccine candidates as well.”

Tal Zaks, Moderna’s chief medical officer
in 16 October 2019 article Unlocking the potential of vaccines built on messenger RNA –
“Moderna scientists demonstrated this last year, creating a multi-sequence mRNA vaccine that prompted cells transfected with the mRNA to express the full pentamer on their surfaces, eliciting protective antibody responses in immunized mice and monkeys4. And last month, the company disclosed that participants in a phase I human trial experienced dose-dependent increases in antibody levels as well. Other prophylactic vaccines in Moderna’s pipeline with promising early clinical data include one for respiratory syncytial virus, a common cause of airway inflammation in infants. And in the case of the company’s mRNA-1653, a dual vaccine against two other recalcitrant respiratory viruses, metapneumovirus and a type of parainfluenza, which are also responsible for severe lung infections, the success of Moderna’s early trials shows that “you can actually now do combinations”

“Moderna is also working on vaccines to tackle emerging infectious diseases such as avian influenza and Zika virus, for which the speed of mRNA manufacturing could be beneficial in the event of a pandemic” Unlocking the potential of vaccines built on messenger RNA, 16 October 2019


You must be logged in to post a comment Login